Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
US Department of Justice
McKinsey
Colorcon
Argus Health
Deloitte
Healthtrust
Harvard Business School
Citi

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,143,212

« Back to Dashboard

Summary for Patent: 8,143,212
Title:Dalbavancin compositions for treatment of bacterial infections
Abstract: The invention provides methods and compositions for treatment of bacterial infections. The composition may be a combination of factors, which include A.sub.0, A.sub.1, B.sub.1, B.sub.2, C.sub.0, C.sub.1, isoB.sub.0, and MAG, in the presence of low level solvent. Methods of the invention include administration of dalbavancin formulations for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimens include multiple dose administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection. Dosing regimens for renal patients are also included.
Inventor(s): Stogniew; Martin (Blue Bell, PA), Colombo; Luigi (Malnate, IT), Ciabatti; Romeo (Novate Milanese, IT)
Assignee: Vicuron Pharmaceuticals Inc. (Morristown, NJ)
Application Number:12/476,785
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,143,212

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc DALVANCE dalbavancin hydrochloride POWDER;IV (INFUSION) 021883-001 May 23, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN. ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,143,212

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,119,061 Dalbavancin compositions for treatment of bacterial infections ➤ Try a Free Trial
6,900,175 Methods of administering dalbavancin for treatment of bacterial infections ➤ Try a Free Trial
7,115,564 Stable pharmaceutical compositions of dalbavancin and methods of administration ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,143,212

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel 230875 ➤ Try a Free Trial
Israel 239913 ➤ Try a Free Trial
Japan 2007534768 ➤ Try a Free Trial
Japan 5207734 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
McKinsey
Covington
Queensland Health
Argus Health
Express Scripts
Farmers Insurance
Cantor Fitzgerald
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.